PDUFA IV Is “Golden Opportunity” To Improve Drug Safety Funding And Staff
Executive Summary
The current round of reauthorization of the Prescription Drug User Fee Act presents a "golden opportunity" to improve FDA's regulation of drug safety, according to the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee
You may also be interested in...
FDA’s Risk/Benefit Decisions Will Be Quantified With Metric From Contractor
A recent request for proposals may signal a shift in FDA's approach to risk/benefit analysis and views on outcome measures, a move some see as bringing more transparency while also shielding the agency from criticism
FDA’s Risk/Benefit Decisions Will Be Quantified With Metric From Contractor
A recent request for proposals may signal a shift in FDA's approach to risk/benefit analysis and views on outcome measures, a move some see as bringing more transparency while also shielding the agency from criticism
FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins
Staffing issues are affecting FDA performance goals as the agency enters the fourth iteration of the Prescription Drug User Fee Act